Pain Modulation in Rheumatoid Arthritis (RA) - Influence of Adalimumab

• Status: Completed
• Trial end date: 2016-11-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to obtain increased knowledge concerning central pain and fatigue processing in rheumatoid arthritis, and how these conditions are influenced by treatment with Tumor Necrosis Factor (TNF) blockade with adalimumab.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska Institutet
• Collaborators: Abbott; Swedish Foundation for Strategic Research; The Swedish Research Council
• Treatments: Adalimumab

Criteria

Inclusion Criteria:

• Age ≥18

• Fulfilling American College of Rheumatology (ACR) criteria for RA.

• Disease duration ≤ 5 years.

• Either under treatment with methotrexate (in a maximum tolerable up to 20 mg/week orally or subcutaneously), or previous treatment with methotrexate withdrawn due to documented side effects.

• Patients should be bio-naïve.

• Disease activity: Disease Activity Score (DAS28)>3.2 and Swollen joint count (SJC)>1 and Tender Joint Count (TJC)>1.

Exclusion Criteria:

For fMRI - left handedness and all forms of metallic implants.

• Fulfilling ACR criteria for fibromyalgia.

• Severe ischemic heart disease.

• Concurrent treatment for depression/anxiety with antidepressant drugs.

• Contraindication to adalimumab.

• Active or latent tuberculosis.

• Chronic infections including hepatitis B or C.

• Malignancy, multiple sclerosis, Systemic lupus erythematosus.

• Other reason as evaluated by the PI.